Examining the Performances of Eli Lilly’s Oncology Products

Oncology products

Eli Lilly and Company’s (LLY) Human Pharmaceutical segment also includes oncology products such as Alimta, Cyramza, and Erbitux.

The oncology portfolio reported revenue growth during the second quarter driven by the strong performances of LLY’s major oncology products.

Examining the Performances of Eli Lilly’s Oncology Products

The above chart shows the revenues of Eli Lilly’s key oncology products since the first quarter of 2017.

Alimta

Eli Lilly’s blockbuster chemotherapy drug, Alimta, reported revenue of ~$555.9 million in the second quarter, a 4% YoY rise compared to $532.9 million in the second quarter of 2017.

This growth was driven by strong sales across US markets and outside US markets. US sales increased ~3%, while sales outside US markets reported 6% growth during the quarter.

Cyramza

Cyramza reported revenue of $218.8 million in the second quarter, a 17% YoY rise compared to $186.3 million in the second quarter of 2017.

This growth was driven by strong sales across US markets as well as outside US markets. US sales increased 10%, while sales outside US markets reported 22% growth in the quarter.

Erbitux

Erbitux reported revenue of $166.4 million in the second quarter, a 5% YoY rise compared to $186.3 million in the second quarter of 2017.

This revenue growth was driven by increased US sales and nearly flat revenues from outside US markets in the quarter.

Lartruvo

Lartruvo reported revenue of $79.9 million in the second quarter, a 69% YoY rise compared to revenue of $47.4 million in the second quarter of 2017.

The drug’s US sales totaled $51 million, while its sales outside US markets totaled $29 million in the quarter.

The iShares US Healthcare ETF (IYH) holds 2.5% in Eli Lilly, 6.5% in Pfizer (PFE), 3.5% in AbbVie (ABBV), and 3.4% in Amgen (AMGN).